Blog
We intend to publish a series of articles describing the evolution of biopharma IP analysis using frontier AI technologies.
8 min readTelling Fallow Ground from Ground Nobody WalkedThe fifteenth article in the rDNA.ai biopharma BD&L series reads the TYK2 target class through whitespace and trajectory analysis, separating fallow ground from cells that only look open because they were never measured.#bd&l#post-foia
7 min readPivoting Upstream Means Fighting Both Current and TimeThe fourteenth article in the rDNA.ai biopharma BD&L series reads the MAPT / anti-Tau target class through forward-looking whitespace and trajectory analysis, showing a field that moved upstream to an already crowded transcript layer.#bd&l#post-foia
8 min readCross-Examining What’s NOT in the EvidenceThe thirteenth article in the rDNA.ai biopharma BD&L series examines the ACTH receptor (MC2R) landscape through the forward-looking whitespace and trajectory layer, testing whether apparent absences in the patent record are actual opportunity.#bd&l#post-foia
7 min readCrowding the Vineyard’s Southern SlopeOn a target with five therapeutic formats and two decades of prosecution, PCSK9 shows why patent density on the established surface says little about where the next drug will act.#bd&l#post-foia
9 min readCharting a Course Through the HeadwindReading the structural IP record of a China-heavy target class to understand what is being bought and what is being restricted.#bd&l#post-foia
8 min readReading the Room Before You Make Your Presence KnownAn introduction to the forward-looking layer of the rDNA.ai toolkit: target-landscape whitespace and trajectory analysis over a structured, provenance-complete knowledge graph of biopharma IP — read here across the cGAS-STING, epigenetic, and TL1A target classes.#bd&l#post-foia
7 min readThe Deals of THIS Decade, Read From the IPFourteen months ago, I predicted that ADCs would be the most successful drug modality of the 2020s. The deal flow since then has validated that prediction, but the structural-IP layer underneath it reveals where the next deals will originate, not just where the next deals will land.#bd&l#post-foia
8 min readSix Blind Men and an ElephantTYK2's structural-IP layer is the elephant that connects the deal flow, the clinical readouts, the cohort statistics, and the issued-claim records — and reading it requires the kind of methodological discipline the rDNA.ai series has been describing across the post-FOIA BD&L toolkit.#bd&l#post-foia
10 min readReading the China Question from the IPAn analysis of the structural-IP layer in the post-2020 CLDN18.2 patent record, read against the backdrop of recent China-originator deal flow and Representative Moolenaar's letter to Treasury Secretary Bessent about the COINS Act.#bd&l#post-foia
7 min readReading the Wake of a SurpriseThis is the sixth article in the rDNA.ai biopharma BD&L series. It looks back at the 2017 GLP-1 indication shift through the lens of a back-test of the KC scoring framework, to see what a rigorous IP-quality reading of the pre-2017 patent record would have said about the foundational IP and the eventual indication shift.#bd&l#post-foia
9 min readDiligence is VigilanceThe final article in a series about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia
8 min readFirst-in-Class is the Only ClassThe fourth in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia
7 min readChoosing the RidgeThe third in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia
6 min readReading the Spec, Not the Press ReleaseThe second in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia
6 min readThe Dog That Stopped BarkingAn introduction to an article series about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia